

West Nile Virus, M07-086 (FTN 07-66)

Catalog No. NR-49926

Product Description: West Nile virus (WNV), M07-086 (FTN 07-66) was isolated from a mosquito (*Culex quinquefasciatus*) in Atlanta, Georgia, USA on July 31, 2007. Each vial contains cell lysate and supernatant from *Cercopithecus aethiops* kidney epithelial cells¹ infected with WNV, M07-086 (FTN 07-66).

Passage History: V1/V3 (Prior to deposit at BEI Resources/BEI Resources); V# = Vero cells¹

Lot^{2,3}: 70005265

Manufacturing Date: 01NOV2017

TEST	SPECIFICATIONS	RESULTS
Identification by Infectivity in Vero cells	Cell rounding and detachment	Cell rounding and detachment
Sequencing of Species-Specific Region (~ 750 base pairs)	≥ 98% identity with WNV, M07-086 (FTN 07-66)	99.6% identity with WNV, M07-086 (FTN 07-66) (GenBank: KC883758)
Titer by TCID₅₀ Assay^{4,5} in Vero cells¹ by Cytopathic Effect	Report results	8.9 × 10 ⁷ TCID ₅₀ per mL
Amplification of WNV Sequence by RT-PCR	~ 920 base pair amplicon	~ 920 base pair amplicon
Sterility (22-day incubation) Harpo's HTYE broth ⁶ , 37°C and 26°C, aerobic Trypticase soy broth, 37°C and 26°C, aerobic Sabouraud broth, 37°C and 26°C, aerobic Blood agar, 37°C, aerobic Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic DMEM with 10% FBS, 37°C and 5% CO ₂	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination Agar and broth culture (14-day incubation at 37°C) DNA detection by PCR of extracted Test Article nucleic acid	None detected None detected	None detected None detected

¹Vero: ATCC® CCL-81™

²The second viral passage at BEI Resources was performed by polyethylenimine (Polyplus-transfection® SA jetPEI® 101-10)-mediated transfection of extracted viral nucleic acid in order to remove contaminating mycoplasma.

³Grown in Eagle's Minimum Essential Medium containing Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate (ATCC® 30-2003) supplemented with 2% fetal bovine serum (ATCC® 30-2020) for 5 days at 37°C with 5% CO₂

⁴The Tissue Culture Infectious Dose 50% (TCID₅₀) endpoint is the 50% infectious endpoint in cell culture. The TCID₅₀ is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD₅₀) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID₅₀ provides a measure of the titer (or infectivity) of a virus preparation.

⁵5 days at 37°C and 5% CO₂

⁶Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Heather Couch/

Heather Couch

12 SEP 2018

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.



BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370

Fax: 703-365-2898